Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management

Indian Journal of Medical Research

Volumn 145, Issue March, 2017, Pages 271-293

  Prasad, Rajendra ^a   Singh, Abhijeet ^a   Balasubramanian, Viswesvaran ^a   Gupta, Nikhil ^b  

^a UNIVERSITY OF DELHI   (India)

^b Era Medical College   (India)

Author keywords

Diagnosis; Epidemiology; Extensively drug; HIV; India; Line drugs; Multidrug; Pregnancy; Resistant tuberculosis; Second; XDR TB

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; BEDAQUILINE; CAPREOMYCIN; CILASTATIN PLUS IMIPENEM; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; DELAMANID; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; NITROIMIDAZOLE; OFLOXACIN; POLYPEPTIDE ANTIBIOTIC AGENT; PRETOMANID; PROTIONAMIDE; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; THIOAMIDE; UNINDEXED DRUG;

ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; BARRIER CONTRACEPTION; BREAST FEEDING; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); CONDOM; CONTRACEPTION; DRUG SAFETY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INDIA; META ANALYSIS (TOPIC); MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; OPTIC NEURITIS; PEDIATRICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; REVIEW; RISK FACTOR; RUSSIAN FEDERATION; SOUTH AFRICA; SPUTUM CULTURE; SYSTEMATIC REVIEW (TOPIC); THORAX RADIOGRAPHY; TREATMENT DURATION; TUBERCULOSIS CONTROL; COMPLICATION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY; VIROLOGY;

HIV; HIV INFECTIONS; HUMANS; INDIA; MYCOBACTERIUM TUBERCULOSIS; RISK FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85026806895     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: 10.4103/ijmr.IJMR_177_16     Document Type: Review

References (101)

1. Shah NS, Wright A, Drobniewski F. Extreme drug resistance in tuberculosis (XDR-TB): Global survey of supranational reference laboratories for Mycobacterium tuberculosis with resistance to second-line drugs. Int J Tuberc Lung Dis 2005; 9: S77.
2. th Conference on Retroviruses and Opportunistic Infections; 7 February 2006; Denver, Colorado, United States of America; 2006.
3. Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55: 301-5.
4. Centers for Disease Control and Prevention (CDC). Notice to readers: Revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 2006; 55: 1176.
5. Migliori GB, Loddenkemper R, Blasi F, Raviglione MC. 125 years after Robert Koch’s discovery of the tubercle bacillus: The new XDR-TB threat. Is “science” enough to tackle the epidemic? Eur Respir J 2007; 29: 423-7.
6. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva: WHO; 2008.
7. th ed. WHO/HTM/TB/2015.22. Geneva: WHO; 2015.
8. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-80.
9. Migliori GB, Ortmann J, Girardi E, Besozzi G, Lange C, Cirillo DM, et al. Extensively drug-resistant tuberculosis, Italy and Germany. Emerg Infect Dis 2007; 13: 780-2.
10. Migliori GB, Besozzi G, Girardi E, Kliiman K, Lange C, Toungoussova OS, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623-6.
11. Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007; 45: 1290-5.
12. Lai CC, Tan CK, Huang YT, Chou CH, Hung CC, Yang PC, et al. Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan. Clin Infect Dis 2008; 47: e57-63.
13. Banerjee R, Allen J, Westenhouse J, Oh P, Elms W, Desmond E, et al. Extensively drug-resistant tuberculosis in California, 1993-2006. Clin Infect Dis 2008; 47: 450-7.
14. Chan ED, Strand MJ, Iseman MD. Treatment outcomes in extensively resistant tuberculosis. N Engl J Med 2008; 359: 657-9.
15. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563-74.
16. Eker B, Ortmann J, Migliori GB, Sotgiu G, Muetterlein R, Centis R, et al. Multidrug-and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis 2008; 14: 1700-6.
17. Keshavjee S, Gelmanova IY, Farmer PE, Mishustin SP, Strelis AK, Andreev YG, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: A retrospective cohort study. Lancet 2008; 372: 1403-9.
18. Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 2008; 47: 496-502.
19. Bonilla CA, Crossa A, Jave HO, Mitnick CD, Jamanca RB, Herrera C, et al. Management of extensively drug-resistant tuberculosis in Peru: Cure is possible. PLoS One 2008; 3: e2957.
20. Punga VV, Jakubowiak WM, Danilova ID, Somova TR, Volchenkov GV, Kazionnyy BY, et al. Prevalence of extensively drug-resistant tuberculosis in Vladimir and Orel regions, Russia. Int J Tuberc Lung Dis 2009; 13: 1309-12.
21. Liu CH, Li L, Chen Z, Wang Q, Hu YL, Zhu B, et al. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: A 13-year experience. PLoS One 2011; 6: e19399.
22. Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E, Astrauko A, van Gemert W, et al. Alarming levels of drug-resistant tuberculosis in Belarus: Results of a survey in Minsk. Eur Respir J 2012; 39: 1425-31.
23. Balabanova Y, Radiulyte B, Davidaviciene E, Hooper R, Ignatyeva O, Nikolayevskyy V, et al. Risk factors for drug-resistant tuberculosis patients in Lithuania, 2002-2008. Eur Respir J 2012; 39: 1266-9.
24. Ulmasova DJ, Uzakova G, Tillyashayhov MN, Turaev L, van Gemert W, Hoffmann H, et al. Multidrug-resistant tuberculosis in Uzbekistan: Results of a nationwide survey, 2010 to 2011. Euro Surveill 2013; 18: pii: 20609.
25. Kuksa L, Riekstina V, Leimane V, Ozere I, Skenders G, Van den Bergh R, et al. Multi- and extensively drug-resistant tuberculosis in Latvia: Trends, characteristics and treatment outcomes. Public Health Action 2014; 4 (Suppl 2): S47-53.
26. Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martín-Casabona N, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13: 380-7.
27. Kam KM, Yip CW. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus. Int J Tuberc Lung Dis 2004; 8: 760-6.
28. Pardini M, Iona E, Varaine F, Karakozian H, Arzumanian H, Brunori L, et al. Mycobacterium tuberculosis drug resistance, Abkhazia. Emerg Infect Dis 2005; 11: 501-3.
29. Masjedi MR, Farnia P, Sorooch S, Pooramiri MV, Mansoori SD, Zarifi AZ, et al. Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran. Clin Infect Dis 2006; 43: 841-7.
30. th Global Report. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO; 2008.
31. World Health Organization. Multidrug and Extensively Drug-resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. WHO/HTM/TB/2010.3. Geneva, Switzerland: WHO; 2010.
32. World Health Organization. Global tuberculosis report 2016. WHO/HTM/TB/2016.13. Geneva, Switzerland: WHO; 2016.
33. Jain S, Rodrigues C, Mehta A, Udwadia ZF. High prevalence of XDR-TB from a tertiary care hospital in India. In: Proceedings of the American Thoracic Society International Conference, May 2007. San Francisco, USA; 2007. [Abstract A510].
34. Mondal R, Jain A. Extensively drug-resistant Mycobacterium tuberculosis, India. Emerg Infect Dis 2007; 13: 1429-31.
35. Singh S, Sankar MM, Gopinath K. High rate of extensively drug-resistant tuberculosis in Indian AIDS patients. AIDS 2007; 21: 2345-7.
36. Jose L, Mundayoor M, Ajaykumar R. Annual Report of the Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram. Thiruvananthapuram: RGCB; 2007. p. 220.
37. Rodrigues C. XDR TB-perspectives from a referral tertiary care hospital in Mumbai. In: Sood OP, Sharma SK, editors. Challenges of MDR/XDR tuberculosis in India. Proceedings of Round Table Conference Series No. 22. New Delhi, India: Ranbaxy Science Foundation; 2008. p. 39-42.
38. Michael JS, Shalini BE, Mathews MS. Drug resistant tuberculosis – An experience of southern states of India. In: Sood OP, Sharma SK, editors. Challenges of MDR/XDR tuberculosis in India. Proceedings of Round Table Conference Series No. 22. New Delhi, India: Ranbaxy Science Foundation; 2008. p. 35-8.
39. Ramachandran R, Nalini S, Chandrasekar V, Dave PV, Sanghvi AS, Wares F, et al. Surveillance of drug-resistant tuberculosis in the state of Gujarat, India. Int J Tuberc Lung Dis 2009; 13: 1154-60.
40. Dhingra VK, Malik S, Hanif M, Arora VK. XDR tuberculosis: A report from the New Delhi tuberculosis centre, India. J Coll Physicians Surg Pak 2009; 19: 133-5.
41. Sharma SK, George N, Kadhiravan T, Saha PK, Mishra HK, Hanif M. Prevalence of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: A retrospective hospital-based study. Indian J Med Res 2009; 130: 392-5.
42. Datta BS, Hassan G, Kadri SM, Qureshi W, Kamili MA, Singh H, et al. Multidrug-resistant and extensively drug resistant tuberculosis in Kashmir, India. J Infect Dev Ctries 2009; 4: 19-23.
43. Rajasekaran S, Chandrasekar C, Mahilmaran A, Kanakaraj K, Karthikeyan DS, Suriakumar J. HIVcoinfection amongmultidrug resistant and extensively drug resistant tuberculosis patients – A trend. J Indian Med Assoc 2009; 107: 281-2, 284-6.
44. Paramasivan CN, Rehman F, Wares F, Sundar Mohan N, Sundar S, Devi S, et al. First- and second-line drug resistance patterns among previously treated tuberculosis patients in India. Int J Tuberc Lung Dis 2010; 14: 243-6.
45. Balaji V, Daley P, Anand AA, Sudarsanam T, Michael JS, Sahni RD, et al. Risk factors for MDR and XDR-TB in a tertiary referral hospital in India. PLoS One 2010; 5: e9527.
46. Chakraborty N, De C, Bhattacharyya S, Mukherjee A, Santra S, Banerjee D, et al. Drug susceptibility profile of Mycobacterium tuberculosis isolated from HIV infected and uninfected pulmonary tuberculosis patients in Eastern India. Trans R Soc Trop Med Hyg 2010; 104: 195-201.
47. Khanna A, Raj VS, Tarai B, Sood R, Pareek PK, Upadhyay DJ, et al. Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. Antimicrob Agents Chemother 2010; 54: 4789-93.
48. Thomas A, Ramachandran R, Rehaman F, Jaggarajamma K, Santha T, Selvakumar N, et al. Management of multi drug resistance tuberculosis in the field: Tuberculosis Research Centre experience. Indian J Tuberc 2007; 54: 117-24.
49. Myneedu VP, Visalakshi P, Verma AK, Behera D, Bhalla M. Prevalence of XDR TB cases – A retrospective study from a tertiary care TB hospital. Indian J Tuberc 2011; 58: 54-9.
50. James P, Gupta R, Christopher DJ, Thankagunam B, Veeraraghavan B. MDR- and XDR-TB among suspected drug-resistant TB patients in a tertiary care hospital in India. Clin Respir J 2011; 5: 19-25.
51. Porwal C, Kaushik A, Makkar N, Banavaliker JN, Hanif M, Singla R, et al. Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region. PLoS One 2013; 8: e55299.
52. Dholakia YN, Shah DP. Clinical profile and treatment outcomes of drug-resistant tuberculosis before directly observed treatment strategy plus: Lessons for the program. Lung India 2013; 30: 316-20.
53. Lakshmipathy D, Ramasubban G, Lily Kulandai LT, Sridhar R, Narahari MH, Meenakshi N. Extensively drug resistant tuberculosis (XDR-TB) by phenotypic drug susceptibility using BACTEC Micro MGIT culture system – A pilot study in hospital based population in Chennai, India. Int J Curr Microbiol Appl Sci 2014; 3: 129-35.
54. Udwadia ZF, Moharil G. Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai. Lung India 2014; 31: 336-41.
55. Isaakidis P, Das M, Kumar AM, Peskett C, Khetarpal M, Bamne A, et al. Alarming levels of drug-resistant tuberculosis in HIV-infected patients in metropolitan Mumbai, India. PLoS One 2014; 9: e110461.
56. Rao P, Chawla K, Shenoy VP, Mukhopadhyay C, Brahmavar V, Kamath A, et al. Study of drug resistance in pulmonary tuberculosis cases in South Coastal Karnataka. J Epidemiol Glob Health 2015; 5: 275-81.
57. Dalal A, Pawaskar A, Das M, Desai R, Prabhudesai P, Chhajed P, et al. Resistance patterns among multidrug-resistant tuberculosis patients in greater metropolitan Mumbai: Trends over time. PLoS One 2015; 10: e0116798.
58. Mukherjee P, Karmakar PR, Basu R, Lahiri SK. Sociodemographic and clinical profile of multi drug resistant tuberculosis patients: A study at drug resistant tuberculosis centers of Kolkata. IOSR J Dent Med Sci 2015; 14: 52-8.
59. Udwadia ZF, Mullerpattan JB, Shah KD, Rodrigues CS. Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai. Lung India 2016; 33: 253-6.
60. Jain A, Dixit P, Prasad R. Pre-XDR & XDR in MDR and ofloxacin and kanamycin resistance in non-MDR Mycobacterium tuberculosis isolates. Tuberculosis (Edinb) 2012; 92: 404-6.
61. Michael JS, John TJ. Extensively drug-resistant tuberculosis in India: A review. Indian J Med Res 2012; 136: 599-604.
62. Salvo F, Dorjee K, Dierberg K, Cronin W, Sadutshang TD, Migliori GB, et al. Survey of tuberculosis drug resistance among Tibetan refugees in India. Int J Tuberc Lung Dis 2014; 18: 655-62.
63. Jeon CY, Hwang SH, Min JH, Prevots DR, Goldfeder LC, Lee H, et al. Extensively drug-resistant tuberculosis in South Korea: Risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis 2008; 46: 42-9.
64. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2014.11. Geneva: WHO; 2014.
65. Ignatyeva O, Balabanova Y, Nikolayevskyy V, Koshkarova E, Radiulyte B, Davidaviciene E, et al. Resistance profile and risk factors of drug resistant tuberculosis in the Baltic countries. Tuberculosis (Edinb) 2015; 95: 581-8.
66. Smith SE, Ershova J, Vlasova N, Nikishova E, Tarasova I, Eliseev P, et al. Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk Oblast, Russia, 2005-2010. Emerg Infect Dis 2015; 21: 1002-11.
67. Karkhanis VS, Joshi JM. Is XDR-TB a sub-group of MDR-TB? Need to reorganize alphabets again! Indian J Tuberc 2012; 59: 187-9.
68. Revised National Tuberculosis Control Programme. Guidelines on Programmatic Management of Drug-resistant Tuberculosis (PMDT) in India. New Delhi: Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare; 2012.
69. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. WHO/HTM/TB/2016.04. Geneva: WHO; 2016.
70. Palomino JC. Nonconventional and new methods in the diagnosis of tuberculosis: Feasibility and applicability in the field. Eur Respir J 2005; 26: 339-50.
71. Furin J. The clinical management of drug-resistant tuberculosis. Curr Opin Pulm Med 2007; 13: 212-7.
72. Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010; 48: 1683-9.
73. World Health Organization. The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs, policy guidance. WHO/HTM/TB/2016.07. Geneva: WHO; 2016.
74. Theron G, Peter J, Richardson M, Barnard M, Donegan S, Warren R, et al. The diagnostic accuracy of the GenoType® MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs. Cochrane Database Syst Rev 2014; 10:CD010705.
75. Singh AK, Maurya AK, Kant S, Umrao J, Kushwaha RAS, Nag VL, et al. Rapid detection of drug resistance and mutational patterns of extensively drug-resistant strains by a novel GenoType® MTBDRsl assay. J Postgrad Med 2013; 59: 179-85.
76. ts. PLoS One 2012; 7: e49433.
77. TB India 2016; Revised National Tuberculosis Control Programme: Annual Status Report. New Delhi, India: Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare; 2016.
78. Sloan DJ, Lewis JM. Management of multidrug-resistant TB: Novel treatments and their expansion to low resource settings. Trans R Soc Trop Med Hyg 2016; 110: 163-72.
79. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-32.
80. Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393-400.
81. Gupta R, Geiter LJ, Wells CD, Gao M, Cirule A, Xiao H. Delamanid for extensively drug-resistant tuberculosis. N Engl J Med 2015; 373: 291-2.
82. Wallis RS, Dawson R, Friedrich SO, Venter A, Paige D, Zhu T, et al. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS One 2014; 9: e94462.
83. Heinrich N, Dawson R, du Bois J, Narunsky K, Horwith G, Phipps AJ, et al. Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. J Antimicrob Chemother 2015; 70: 1558-66.
84. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011; 204: 1951-9.
85. World Health Organization. Tuberculosis control in the South-East Asia region: Annual TB report 2015. Geneva: WHO; 2015. Available from: http://www.searo.who.int/tb/annual-tb-report-2015, accessed on July 19, 2016.
86. Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: A retrospective cohort study. Lancet 2010; 375: 1798-807.
87. Kvasnovsky CL, Cegielski JP, Erasmus R, Siwisa NO, Thomas K, der Walt ML. Extensively drug-resistant TB in Eastern Cape, South Africa: High mortality in HIV-negative and HIV-positive patients. J Acquir Immune Defic Syndr 2011; 57: 146-52.
88. Sotgiu G, Ferrara G, Matteelli A, Richardson MD, Centis R, Ruesch-Gerdes S, et al. Epidemiology and clinical management of XDR-TB: A systematic review by TBNET. Eur Respir J 2009; 33: 871-81.
89. Migliori GB, Sotgiu G, D’Ambrosio L, Centis R, Lange C, Bothamley G, et al. TB and MDR/XDR-TB in European Union and European Economic Area countries: Managed or mismanaged? Eur Respir J 2012; 39: 619-25.
90. Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, et al. Resistance to fluoroquinolones and second-line injectable drugs: Impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-68.
91. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: Systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
92. Sotgiu G, Centis R, D’Ambrosio L, Alffenaar JW, Anger HA, Caminero JA, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: Systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-42.
93. Pietersen E, Ignatius E, Streicher EM, Mastrapa B, Padanilam X, Pooran A, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: A cohort study. Lancet 2014; 383: 1230-9.
94. Gopal M, Padayatchi N, Metcalfe JZ, O’Donnell MR. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013; 17: 1001-7.
95. Blöndal K, Viiklepp P, Guðmundsson LJ, Altraja A. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 2012; 16: 1228-33.
96. Pomerantz M, Madsen LA, Goble M, Iseman MD. Surgical management of resistant mycobacterial tuberculosis and other mycobacterial pulmonary infections. Ann Thorac Surg 1991; 52: 1108-11.
97. Vashakidze S, Gogishvili S, Nikolaishvili K, Dzidzikashvili N, Tukvadze N, Blumberg HM, et al. Favorable outcomes for multidrug and extensively drug resistant tuberculosis patients undergoing surgery. Ann Thorac Surg 2013; 95: 1892-8.
98. Meintjes G. Management of drug-resistant TB in patients with HIV co-infection. J Int AIDS Soc 2014; 17 (4 Suppl 3): 19508.
99. Mukherjee JS, Joseph JK, Rich ML, Shin SS, Furin JJ, Seung KJ, et al. Clinical and programmatic considerations in the treatment of MDR-TB in children: A series of 16 patients from Lima, Peru. Int J Tuberc Lung Dis 2003; 7: 637-44.
100. Zumla A, Abubakar I, Raviglione M, Hoelscher M, Ditiu L, McHugh TD, et al. Drug-resistant tuberculosis - current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis 2012; 205 (Suppl 2): S228-40.
101. World Health Organization. The global MDR-TB and XDR-TB response plan 2007-2008. WHO/HTM/TB/2007.387. Geneva: WHO; 2007.